Harbour BioMed Achieves Annual Profit for the First Time in 2023: Total Revenue Reaches $89.5 Million

Harbour BioMed, a leading biopharmaceutical company, has announced its financial performance for the year 2023. The company achieved a significant milestone by realizing its first-ever annual financial profit. With a total revenue of $89.5 million, representing a remarkable growth of 119.9% compared to the previous year, Harbour BioMed demonstrated its success in various areas, including product licensing, research services, and technological partnerships. This article delves into Harbour BioMed' financial highlights and its innovative product pipeline.

Financial Success and Revenue Growth:

Harbour BioMed reported a total profit of $22.76 million for the year ending December 31, 2023, marking its inaugural annual financial profitability. The company's revenue composition primarily consisted of product licensing, research services, and technological partnerships. The substantial increase in total revenue can be attributed to successful collaborations with Pfizer, Cullinan Oncology, and Corning Biotech. In 2023, Harbour BioMed recorded a total revenue of $89.5 million, a significant surge from $40.66 million in 2022.

Investment in Research and Development:

During the reporting period, Harbour BioMed invested a total of $45.08 million in research and development (R&D), reflecting a decrease of 66.6% compared to the previous year's investment of $135 million. This decline in R&D expenditure was influenced by two factors: optimization of investments in proprietary clinical projects and early-stage discovery programs, as well as efficient cost control measures. The company's strategic approach to R&D investment ensures focused and streamlined development of its product pipeline.

Product Portfolio and Milestones:

Harbour BioMed, known for its global innovation and differentiated product pipeline, operates as a subsidiary brand parallel to Nona Biotech. The company specializes in the field of oncology and immunological diseases, with over ten differentiated drug candidates, four of which are in clinical stages. Key products in Harbour BioMed' portfolio include HBM9161 (Bartoli monoclonal antibody), HBM4003 (Prusubai monoclonal antibody), HBM7008, and HBM1020. Bartoli monoclonal antibody, a rapidly advancing FcRn inhibitor in the Greater China region, holds immense potential as a breakthrough treatment for various autoimmune diseases. In March 2023, positive results from the Phase III trial for the treatment of systemic myasthenia gravis were announced, marking the company's first completion of a Phase III clinical trial and preparation for commercialization, providing hope for numerous patients.

Prusubai monoclonal antibody, developed on the HCAb platform, represents a next-generation fully human anti-CTLA-4 antibody. It is the world's first fully human anti-CTLA-4 antibody to enter clinical stages. Harbour BioMed continues to accelerate the global clinical development of Prusubai monoclonal antibody for various solid tumors. Ongoing trials in neuroendocrine tumors and hepatocellular carcinoma have already shown positive data in terms of efficacy and safety.

HBM7008, developed on the HBICE® platform, is a novel bispecific antibody targeting B7H4 and 4-1BB, making it another testament to Harbour BioMed' strong research and development capabilities. Even in the preclinical stage, HBM7008 has demonstrated promising therapeutic efficacy and safety characteristics due to the company's expertise in biology and antibody engineering. In February 2023, a regional partnership development agreement was reached with Cullinan Oncology to expedite research progress in the United States, Europe, and Australia, thereby maintaining a global development advantage.

HBM1020, a globally pioneering fully human monoclonal antibody targeting B7H7, was developed using the HarbourMice® H2L2 transgenic mouse platform. B7H7, an immune regulatory molecule belonging to the B7 family, plays a crucial role in tumor cell evasion from immune surveillance independent of PD-L1 expression. HBM1020 is the world's first officially approved monoclonal antibody targeting B7H7 to enter clinical stages. With its outstanding product design and target characteristics, HBM1020 aims to address significant unmet medical needs in the field of solid tumor treatment. Under the driving force of the company's leading drug innovation and discovery engine, several new products have been pushed into clinical trials. HBM1020, HBM1022, HBM1007, and HBM9033 received IND (Investigational New Drug) approval from the U.S. FDA in 2023, while HBM9027 obtained IND approval in the first quarter of 2024. Additionally, several preclinical candidates, including HBM7004, HBM1047, and HBM9014, have demonstrated immense development potential.